Autobrains
Expected to launch in Q4 2024, Autobrains' new vehicle production features an advanced ADAS solution, harnessing cutting-edge Artificial Intelligence to provide drivers with unparalleled assistance.
TEL AVIV, ISRAEL and MUNICH, GERMANY / ACCESSWIRE / May 21, 2024 / Autobrains, a disrupter in automotive artificial intelligence (AI) and Advanced Driver Safety Systems (ADAS), today announced their nomination, which will see Autobrains' innovative software, Liquid AI, deployed in a new line of vehicles developed by a leading Chinese Electric Vehicle manufacturer. Production of these new vehicles is expected to begin during Q4, 2024.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.Autobrains Announces Design Win for ADAS Solution Implementing Liquid AI in Chinese EV Expected to launch in Q4 2024, Autobrains' new vehicle production features an advanced ADAS solution, harnessing cutting-edge Artificial Intelligence
Autobrains has established the development of revolutionary AI solutions, including its flagship Liquid AI technology, which has been central to addressing the most complex challenges in today's automotive AI landscape. While details of the partner remain confidential, the collaboration is set to redefine industry standards and accelerate the adoption of advanced driver-assistance systems across the automotive sector.
Igal Raichelgauz, Founder and CEO of Autobrains, commented, "Teaming up with a leading Chinese automotive player reinforces the exceptional performance and adaptability of our advanced AI systems. By integrating our cutting-edge technology with their robust manufacturing capabilities, we are creating a new paradigm shift for what AI in vehicles can achieve. Our shared commitment to innovation will help accelerate the adoption of AI-driven solutions, enhancing the driving experience and pushing the entire industry forward."
Autobrains is set to redefine the future of driving in China and globally with its pioneering technology - known for its exceptional edge case detection, remarkably low power consumption, and for being hardware agnostic. This strategic partnership and implementation of Liquid AI technology into mass production exemplifies Autobrains' commitment to global market expansion and underscores our relentless pursuit of innovation in the automotive sector.
For more information about Autobrains and its cutting-edge Liquid AI and ADAS solutions, please visit autobrains.ai
About Autobrains
Autobrains is a leading AI company in the automotive industry. Autobrains invented and developed a paradigm-shifting AI technology: Liquid AI - backed by 250+ patents addressing autonomous driving challenges. Implementing this unique AI technology for ADAS applications disrupts the market with its unprecedented perception capabilities, low compute requirements, and agnosicity to sensors and SoCs. The company is backed by strategic investors including Temasek, Knorr-Bremse AG, BMW i Ventures, Toyota Ventures, VinFast, Continental AG, and Autel.
Learn more: https://autobrains.ai.
Contact Information
Sophia Eichler
Director of Marketing
media@autobrains.ai
+49 15167066494
SOURCE: Autobrains Technologies
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release
On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom